ChromaDex Reports Third Quarter 2009 Financial Results

ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the third quarter of 2009. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.01 per share for the thirteen week period ended October 3, 2009.

As of October 3, 2009, cash, cash equivalents, and marketable securities totaled $501,425.

"We are very pleased with our performance this quarter," said Frank Jaksch, CEO and co-founder of ChromaDex. "Despite continued tough overall economic conditions we continue to grow our top line revenue."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during the third quarter of 2009 of $1,433,086 as compared to $1,069,003 for the same period in 2008. The net loss attributable to common stockholders for the thirteen weeks ended October 3, 2009, was $177,544 as compared to a net loss of $710,347 for the same period in 2008. The lower net loss in the third quarter of 2009 as compared to the same period in 2008 was primarily attributable to [non-recurring] expenses in 2008 related to a private placement and the reverse merger acquisition of Cody Resources, Inc. coupled with an increase in revenues. The Company notes that as a result of its closing of the reverse merger acquisition of Cody Resources, Inc. on June 20, 2008, investors are cautioned that the Company's historical performance for that year is not directly comparable.

About ChromaDex

ChromaDex is a leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

    ChromaDex Corporation and Subsidiaries
    Consolidated Statements of Operations (Unaudited)
    For the Three Month Periods ending October 3, 2009 and September 27, 2008

                                                    Three Months Ended
                                          October 3, 2009   September 27, 2008


    Sales                                      $1,433,086        $1,069,003
    Cost of goods sold                            953,043           881,839
                                                  -------           -------
        Gross profit                              480,043           187,164
                                                  -------           -------

    Operating expenses:
      Selling                                     190,153           178,439
      General and administrative                  463,618           704,018
                                                  -------           -------
                                                  653,771           882,457
                                                  -------           -------

        Operating loss                           (173,728)         (695,293)
                                                 --------          --------

    Nonoperating (income) expenses:
      Interest expense                              3,938            27,208
      Interest income                                (122)          (12,154)
                                                     ----           -------
                                                    3,816            15,054
                                                    -----            ------

        Net loss                                $(177,544)        $(710,347)
                                                =========         =========


    Basic and Diluted loss per common share        $(0.01)           $(0.02)
                                                   ======            ======

    Basic and Diluted average common shares
     outstanding                               28,838,216        28,600,943
                                               ==========        ==========

    See Notes to Consolidated Financial Statements.

SOURCE ChromaDex Corp.

http://www.chromadex.com

Related terms: accounting, acquisition, ceo, contract, financial results, food, law, market, merger, otc, Private Placement, product development, products, property, research, revenue, sales, securities, standards